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Background: Use of inhaled tobramycin therapy for treatment of Pseudomonas aeruginosa infections in young children with cystic ﬁbrosis (CF) is
increasing. Safety data for pre-school children are sparse.
Methods: The aim of this study was to assess the safety of tobramycin solution for inhalation (TOBI®-TSI) administered twice daily for 2 months/
course concurrently to intravenous (IV) tobramycin during P. aeruginosa eradication therapy in children (0–5 years). Audiological assessment and
estimation of glomerular ﬁltration rate (GFR) was measured prior to any exposure and end of the study.
Results: Data were available from 142 patients who were either never exposed to aminoglycosides (n = 39), exposed to IV aminoglycosides only
(n = 36) or exposed to IV + TSI (n = 67). Median exposure to TSI was 113 days [59, 119]. Comparison of effects on audiometry results and GFR,
showed no detectable difference between the groups.
Conclusions: Use of TSI and IV tobramycin in pre-school children with CF was not associated with detectable renal toxicity or ototoxicity.
© 2014 European Cystic Fibrosis Society. Published by Elsevier B.V. Open access under CC BY-NC-ND license.Keywords: Aminoglycoside; Tobramycin solution for inhalation; Paediatrics; Cystic ﬁbrosis; Adverse events1. Background
Inhaled tobramycin has been a mainstay of treatment for those
with cystic fibrosis (CF) for many years due to the excellent
activity against Pseudomonas aeruginosa (P. aeruginosa) [1],
the most common airway pathogen in CF. Tobramycin remains
active after aeroionisation and is poorly absorbed across⁎ Corresponding author at: Queensland Children's Respiratory Centre, Royal
hildren's Hospital, Herston Rd, Herston, QLD 4029, Australia. Tel.: +61 7
6361932; fax: +61 7 36364230.
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Oepithelial surfaces, thus achieving high concentrations in
bronchial secretions with minimal systemic absorption [2].
Serum tobramycin concentrations after inhaled tobramycin
are generally very low, with serum to sputum ratios of ap-
proximately 1% [3]. As a result, inhalation of tobramycin is
anticipated to be associated with minimal systemic toxicity [4]
in comparison to intravenous (IV) therapy which is known
to be associated with increased risk of nephrotoxicity and
ototoxicity [5–7].
Well recognised adverse events (AE) associated with amino-
glycosides, and particularly tobramycin, include otovestibular
and renal toxicity. Although precise mechanisms are unclear,pen access under CC BY-NC-ND license.
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membrane permeability is integral to the ototoxic effects [7].
Similarly, nephrotoxicity is believed to occur as a result of
retention of a portion of the administered dose in the cells of the
proximal tubules of the nephrons [6]. Progression to renal
failure is rare and recovery occurs upon discontinuation in most
cases [8].
Treatment with tobramycin solution for inhalation (TSI),
aimed at eradication of early P. aeruginosa infections is
standard care in North America and frequently used in Europe
and Australasia. There are few studies assessing the safety of
TSI in young children. One small study using 300 mg TSI
inhaled twice daily in 8 preschool children reported no AEs
(changes in serum creatinine, audiometry and bronchospasm
were assessed)[9]. A recent study including children aged 1–12
reported no AEs due to TSI although age of first exposure to TSI
and methods for monitoring AEs were unclear [10]. Several
studies have investigated inhaled tobramycin in older children and
adults and reported very few treatment-related AEs. [1,11–13]
The present study takes advantage of data from the Australasian
Cystic Fibrosis Bronchoalveolar Lavage (ACFBAL) study which
used TSI as part of the P. aeruginosa eradication protocol in
preschool children [14]. Dosage and AE monitoring for IV
tobramycin and TSI were protocol-driven over the entire 5 year
study period, which allowed investigation of the safety profile of
this medication.2. Methods
2.1. Study and patients
The study design, protocol and other outcomes for ACFBAL
study have previously been reported [14]. Briefly, the study
which ended in December 2009, enrolled 170 infants diagnosed
with CF across 8 sites in Australia and New Zealand and followed
up until age 5 years.
Antibiotic treatment for P. aeruginosa infection included
two weeks of IV therapy (once daily tobramycin commencing at
a dose of 10 mg/kg, together with either 100 mg/kg ticarcillin–
clavulanate three times a day or, 50 mg/kg ceftazidime three
times a day). Tobramycin doses were adjusted by measuring 2 h
and 6–14 h post-dose tobramycin concentrations and applying a
linear regression method [15] aiming for an area under the
concentration-time-curve of 100 mg/L.hr (with an acceptable
AUC of 90 to 110 mg/L.h). Upon cessation of IV antibiotics,
children received 56 days of TSI 300 mg (TOBI®) twice daily
via a Pari LC Plus jet nebuliser with mask over a minimum of
15 min, or until nebulisation was complete. Concurrent oral
ciprofloxacin (15 mg/kg twice daily) was administered for the
first 28 days. As well as being used to treat proven infections
with P. aeruginosa, IV antibiotics (including tobramycin) were
administered to children who did not respond to outpatient
treatment for a pulmonary exacerbation where P. aeruginosawas
not detected upon microbiological culture. In these cases, the
children did not receive follow-up treatment with TSI after
completion of IV antibiotics.For the present study all patients enrolled into the ACFBAL
study with data available prior to any aminoglycoside exposure
were included in order to compare the safety and toxicity
between 3 distinct groups. The first group was designated
‘never exposed’ and children assigned to this group received
neither IV aminoglycosides nor TSI during the 5 years. The
second group; the ‘IV only’ group included children who received
IV aminoglycosides treatment, predominantly tobramycin, but no
TSI in the 5 years. Lastly, the third group, called the ‘IV and TSI’
group, as children assigned to this group received both IV
aminoglycosides and inhaled TSI.
2.2. Safety assessment
Data collection included serum tobramycin concentration
one hour after administration of TSI; renal function monitoring via
estimation of glomerular filtration rate (GFR) and measurement of
serum creatinine; audiometric function prior to and following
exposure; and reported AEs. All comparisons were done between
the first ever record and the closest to end of the study, unless
specified otherwise.
2.2.1. Serum tobramycin concentration
The first dose of TSI was generally administered 24 h after
cessation of IV tobramycin and normally after this first TSI
dose tobramycin concentrations were measured 60 min. after
the start of inhalation. Blood samples for tobramycin assay
were collected via venipuncture or finger-prick depending on
local practice. Investigations in April 2004 [16], demonstrated
evidence for skin contamination with tobramycin after inhaled
therapy affecting serum levels detected by finger prick. Conse-
quently, samples taken via finger prick collections were analysed
separately. The reported lower limit of quantification (LOQ) of
tobramycin was 0.2 mg/L and thus any concentrations reported
below LOQ were set to a value of LOQ/2.
2.2.2. Renal function
Cumulative renal toxicity over the study duration was assessed
by comparing creatinine clearance at baseline (prior to aminogly-
cosides exposure) and creatinine clearance at the last measure-
ment closest to end of study. These were summarised for each
aminoglycoside group and mean differences compared. Creatinine
clearance was assessed by estimating GFR using the Schwartz
equation for pediatric patients[17].
To monitor the impact of an IV tobramycin course prior to
TSI treatment on renal function, changes in serum creatinine
concentrations measured within a patient during the same IV
course were compared.
2.2.3. Audiometric function
Due to the age of the children in the study, the appropriate
testing modality used at each audiometric assessment through-
out the study was determined by the administering pediatric
audiologists at each centre. Children were scheduled for screening
audiometric assessments at baseline (b6 months of age prior to
aminoglycoside exposure) and at 5 years at study completion.
Those receiving inhaled TSI were scheduled for audiometry after
Table 1
Participants and exposure to IV tobramycin and TSI.
‘Never expose’ ‘IV only’ ‘IV + TSI’
Number of patients 39 36 67
% Male 64 50 42
Weight at enrollment, z-score −0.61 [1.0] a −0.84 [1.2] a −0.79 [1.1] a
Height at enrollment, z-score n = 38
−0.36 [1.2] a
n = 35
−0.62 [1.1] a
n = 62
−0.57 [1.3] a
Age at first exposure to IV
aminoglycoside (months)
– 18 [6.8, 34] b 19 [7.1, 33[ b
Age at first exposure to TSI
(months)
– – 28 [15] a
Days on IV aminoglycosides 0 13 [6.5, 19] b 31 [19, 55] b
Days on TSI 0 0 113 [59, 119] b
a Mean [SD].
b Median [interquartile range].
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ioural assessment including Visual Reinforcement Orientation
Audiometry (VROA), Play Audiometry and Pure Tone Audiom-
etry (PTA) to establish hearing thresholds and nature of any
hearing loss present (conductive or sensorineural). Baseline testing
may have included Auditory Brainstem Response (ABR) to assess
neural function and predict hearing levels in infants in lieu of
behavioural results. The ABRs were performed using a ‘feed and
wrap’ natural sleep protocol in all but 6 infants, who had ABRs
collected under general anaesthesia as they were performed on the
same day as the baseline BAL Tympanometry was obtained where
possible to assess middle ear function. Otoacoustic emissions
(OAE) were performed in some centres involved in the study but
not all, and are not reported formally.
2.3. Statistical analysis
Weight and height z scores were calculated from the 2000 CDC
Growth Reference Charts (http://www.cdc.gov/growthcharts).
Means and standard deviations (SDs) are presented for normally
distributed data with medians and inter quartile ranges (IQRs)
presented for skewed data. The change in GRFwas analysed using
a paired t-test while group comparisons of this change were made
using linear regression. Corresponding 95% confidence intervals
(CIs) for mean differences are shown. Non-parametric methods
were used to analyse skewed data: Wilcoxon signed-rank test for
paired data and Kruskal–Wallis when comparing groups. Analysis
was performed using Stata V.12.1 (StataCorp, College Station,
Texas).
3. Results
Of the 170 patients enrolled in the ACFBAL study, 26 patients
received inhaled tobramycin or gentamicin instead of TSI and two
patients did not meet the eligibility criteria, consequently 142
children contributed data to this analysis. There were 39 (27.5%)
children in the ‘never exposed’ to aminoglycosides group, 36
(25.3%) children in the ‘IV only’ group (of which 61% received
tobramycin only, 3% tobramycin and netilmicin, 8% tobramycin
and gentamicin, 25% gentamicin only and 3% gentamicin and
netilmicin), and the remaining 67 (47.2%) children comprised the
group designated ‘IV and TSI’ were exposed to IV aminoglyco-
sides and TSI (75% only to IV tobramycin, 1% to IV gentamicin
only and 24% to IV tobramycin and gentamicin). Children in the
‘IV only’ group represents patients with negative P. aeruginosa
cultures who received IV anti-Pseudomonal therapy based on lack
of response to prior therapy. Demographics were well matched at
baseline (Table 1).
3.1. Serum tobramycin concentration
Children in the ‘IV and TSI’ group received approximately
twice the median number of days of cumulative exposure to IV
aminoglycosides compared with children in the ‘IV only’ group
although the age of first exposure (Table 1) was similar. The
dose of the first course of IV tobramycin administered was
different in the groups, with a mean of 10.3 mg/kg in the ‘IVonly’ group and 12.0 mg/kg in the ‘IV and TSI’ group. This
difference was present over the whole study period; the mean dose
administered being 10.5 mg/kg and 12.1 mg/kg IV tobramycin,
respectively. The median number of days on IV tobramycin for
one IV course was 8 days in the ‘IV only’ group and 13 days in
the ‘IV and TSI’ group.
Children in the ‘IV and TSI’ group received between 1 and 5
([1,2], n = 67) courses of TSI. A course of TSI was defined as
2 months of TSI treatment as part of an eradication treatment.
The median [interquartile range] number of days that patients
received TSI during one course was 58 days [57,60]. In total,
52% of the samples taken revealed serum tobramycin concentra-
tions below 1 mg/l, with 21% of samples being below LOQ. The
median [interquartile range] concentration obtained from blood
collected via finger prick (1.5 mg/l [0.9,4.2], n = 39) was higher
than that from samples taken via venepuncture (0.6 mg/l [0.1,1],
n = 45). The tobramycin concentration measured via finger prick
ranged from 0.1 mg/l to 8.6 mg/l and via venepuncture from
0.1 mg/l to 4 mg/l. As expected, the tobramycin concentrations
measured 1 hour post inhalation of TSI showed low systemic
absorption.
3.2. Serum creatinine and renal function (Table 2)
A total of 37 pairs of serum creatinine concentrations measured
within an IV course (median time between measurements 4 days
[IQR: 2, 9]) in 24 patients were available for comparison. The
first and last median serum creatinine concentrations within an
IV period were 30 μmol/L [IQR: 20, 35] and 20 μmol/L [IQR:
20, 33], respectively. There was no evidence of a difference
between the first and last serum creatinine concentration
within an IV period (median difference 0 μmol/L, [IQR −7, 1],
p = 0.43).
There was a minor difference, of no clinical significance, in
the median GFR at baseline across the three groups. There was
no difference in median serum creatinine concentration at the
end of the study across the groups (p = 0.42, Table 2). The
mean increase in GFR from baseline to study completion was
31 [95% CI 22 to 40]; p b 0.001. However, when adjusting
for the baseline value and looking across aminoglycoside
Table 2
Serum Creatinine, renal and audiometric functioning before exposure to tobramycin and at study completion.
‘Never exposed’
N = 39
‘IV only’
N = 36
‘IV and TSI’
N = 67
Serum creatinine n = 36 n = 27 n = 52
Age (months) at first available serum creatinine record, pre exposure 7.7 [1.1,14] 2.6 [0.99,12] 2.0 [1.1,6.6]
Serum creatinine (μmol/L) at first available record, pre exposure 20 [20,32] 20 [20,23] 20 [20,38]
Age (months) at assessment of serum creatinine at study completion 59 [57,60] 60 [59,61] 60 [59,61]
Serum creatinine (μmol/L) at study completion 33 [26,40] 34 [20,37] 36 [27,40]
Renal Function
GFR (ml/min/1.73 m2) at first available record, pre exposure 101 [84,136] 105 [93,127] 95 [59,110]
GFR (ml/min/1.73 m2) at study completion 111 [98,153] 120 [99,193] 109 [96,147]
Auditory Function n = 29 n = 25 n = 49
Age(months) at first available assessment of auditory function, pre exposure 7.8 [3.6, 12] 4.7 [2.6, 9.4] 5.6 [3.8, 10]
Number with conductive hearing loss at first available record, pre exposure 1 1 6
Age(months) at assessment of auditory function at study completion 60 [59, 61] 61 [60, 62] 61 [60, 62]
Number with conductive hearing impairment at study completion 1 1 5
Number with sensorineural hearing impairment at study completion 0 0 1
Values are shown as median with interquartile range in brackets.
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only’ or ‘IV and TSI’ groups compared to the ‘never exposed’
group (mean difference in GFR increase was 8.8 [95% CI −12
to 30]; p = 0.41 and 5.4 [95% CI −13 to 24]; p = 0.57,
respectively).
When age at baseline and the time between pre- and post-
exposure were added to the model, no difference in outcome
was found. Fig. 1 shows the changes in GFR from the first to
the last available record for the never exposed group and from
pre- to post-exposure for the exposed groups. Fig. 2 shows the
effect of repeated exposure to TSI on the change in GFR from
baseline to the end of study measurement. Cumulative TSI
exposure in days was divided into three groups: 1 course of
TSI, 2 courses of TSI and 3 or more courses of TSI. There was
no evidence of a difference in the change in GFR with 2 courses
or 3+ courses compared to a single course of TSI (mean
difference in GFR increase 1.8 [95% CI −22 to 26]; p = 0.88
and 21 [95% CI −11 to 53]; p = 0.19, respectively).0
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Fig. 1. Change in GFR (ml/min) from prior to aminoglycoside exposure (first)
to study completion (last).3.3. Audiometric function
One child was excluded from audiometric analysis due to
the presence of a congenital sensorineural hearing loss in both
ears. Another child was unable to complete the audiometry
assessments due to co-existent autism. Further 37 of the remaining
140 children did not complete both pre and post audiometric
testing, withdrew from the study, or were exposed to TSI or IV
aminoglycosides prior to their first audiometric exam. Results for
all remaining children are listed in Table 2.
Table 2 shows that the number of patients with normal hearing
at baseline and the study end were 28, 24 and 43 in the ‘never
exposed’, the ‘IV only’ and the ‘IV and TSI’ group, respectively.
Conductive hearing loss or sensorineural hearing impairment
between baseline and at the end of the study was found in 3.4%,
4.0%, and 12% of patients in the ‘never exposed’, the ‘IV only’
and the ‘IV and TSI’ group, respectively. One child in the ‘IV and
TSI’ group was found to have a mild right-sided sensorineural
hearing loss at study end and Fig. 3 shows the audiogram for this
child. This loss could be attributed to ototoxic effects, as baseline-
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Fig. 2. Difference in GFR (glomerular filtration rate) for children exposed to
inhaled tobramycin (TOBI®) by duration of the inhaled tobramycin course.
Fig. 3. Audiogram of child 710 exhibiting a mild hearing loss in the right ear.
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tently received a 300 mg (21.3 mg/kg) IV tobramycin dose instead
of the nebulised TSI additionally to the usual IV tobramycin
prescribed during the hospital admission, which was reported as a
serious AE at the time.
3.4. Other adverse events
The most common AE in children exposed to TSI was voice
alteration (‘husky’, ‘hoarse’ or ‘lost’ voice); reported on one
occasion by 6 children. Other AEs assessed as having a causal
relationship with TSI included: conjunctivitis (n = 2), tinnitus
(n = 1), epistaxis (n = 1), rash (3 episodes in 2 children, n = 1
in the face and on trunk, n = 1 unknown location) and acute
respiratory distress (n = 1). The acute respiratory distress resulted
in cessation of TSI. Further, TSI was withheld from one of the
children with rash until it resolved, but upon reinstitution of TSI the
rash recurred and considered due to TSI which was discontinued
permanently.
4. Discussion
In this study, we were able to prospectively examine every
exposure to IV tobramycin and TIS in children from birth until
5 years of age. We found little evidence for drug-associated
toxicity resulting from the use of IV tobramycin and TSI in
young children with CF.
To achieve best efficacy high peak tobramycin concentra-
tions are required [18], however high and cumulative exposure
to aminoglycosides are linked to ototoxicity [5] and high trough
levels are considered to influence the development of renal
toxicity. In this study, the dosage of tobramycin administered
intravenously was adjusted to achieve an AUC in a predetermined
range. In addition, we adopted a once daily dosing regimen that is
considered at least equally as safe, as multiple daily dosing [19].
This management may have contributed, at least in part, to the
absence of any measureable renal or ototoxic effects in those
exposed to IV tobramycin compared with those who were not.It was found that higher doses and longer duration of IV
tobramycin were administered to those in the ‘IV and TSI’
group, which was likely due to more targeted therapy in this
group to eradicate P. aeruginosa and repeated drug monitoring
leading to dose increases over time. Nonetheless, there was no
difference in tobramycin specific AEs in this group.
While high serum tobramycin concentrations after inhalation
of TSI were detected; mean concentrations were similar to those
previously reported [20,21]. In general, peak serum tobramycin
concentrations are reported to average b1 mg/L after TSI [1,12]
with the highest concentrations being rarely above 4 mg/L
[20,22]. While we are confident that the small numbers of very
high levels we measured were the result of contamination
with deposited TSI at the site of blood collection as reported
previously [16,23] we cannot eliminate the possibility that there
was a higher systemic exposure after administration of TSI in
these children. Higher systemic exposures to TSI have been
reported in those with well-preserved lung function [4] and this
may be relevant for our study patient population.
Nephrotoxicity from inhaled aminoglycosides is rarely
reportedly in children [24] and we found no evidence of
nephrotoxicity in preschool children treated with TSI, some of
whom had repeated courses of the drug. Limitations of using
creatinine concentration as a marker for renal function are
well known, as it is highly dependent on muscle mass, which
changes as children grow. In addition, it is dependent upon diet,
concomitant drug administration and hepatic function, which
are all relevant in children with CF. The updated Schwartz
formula used here to estimate GFR [17] may not be the most
sensitive method for determining early renal dysfunction however
each child served as their own baseline thus minimizing variations
in GFR. GFR did, as expected, increase with age however at the
end of the study there was no difference between the groups,
providing reassurance for no detectable nephrotoxicity with
exposure to IV tobramycin and TSI. We also found no relationship
between cumulative exposure to TSI and tracking of GFR,
mirroring and extending the previous report of Pedersen et al.
for IV tobramycin exposure [25]. Ideally, more sensitive and
predictive means of monitoring early renal impairment could be
used in the future.
Studies of ototoxicity have conventionally used audiometric
methodologies that require co-operation from the individual
being assessed and this was an issue for our children prior to
exposure as they were infants. Despite these difficulties we did
employ effort-independent methods of audiometry to obtain
baseline assessments of nerve and cochlear functioning and all
testing was done by paediatric audiologists. We found one child
with congenital hearing loss who was excluded from analysis as
any deterioration in hearing thresholds could be attributed to
congenital rather than ototoxic effects.
One child in the ‘IV and TSI’ group was found to have a
mild right-sided sensorineural hearing loss at study end which
was not noted at baseline assessment. The same child inadver-
tently received 300 mg tobramycin as IV instead of TSI, which
highlights the importance of drug administration errors which can
occur when different delivery methods of the same drug are used.
All other children exhibited either normal hearing, or conductive
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to tobramycin use are not largely evident in this young cohort.
Few studies exist within this age range. Thomsen et al. reported
no significant ototoxic effects of repeated courses of IV
tobramycin administered over 2 week periods in young Danish
children with CF with only one child exhibiting a transient high
tone hearing loss [26]. Similarly, in spite of serum tobramycin
concentrations up to 9.9 mg/l after inhalation of an intravenous
form of tobramycin, Mukhopadhyay et al. were unable to find
any significant abnormalities in their study of serial evoked
response audiometry in children with CF [27].
Studies investigating ototoxic effects of tobramycin in older
children and adults with CF suggest that a cumulative effect or
genetic component may be involved [28,29]. Interestingly,
there does not appear to be a correlation between aminoglyco-
side dose, peak serum levels, or number of courses, and level of
hearing loss in CF patients [30]. Others suggest that the CF
condition itself may actually provide a level of protection against
the effects of aminoglycoside-based ototoxicity [30].
Some treatment-related AEs were found. Voice alteration
was the most common adverse event in this group of 0–5 year
olds. This was consistent with the known adverse event profile
of TSI and previous reports in those with CF aged 6 years and
older and those in the EPIC and ELITE studies [1,11,12] where
the most common side effects were cough and dysphonia, also
common to other inhaled therapies.
Thus, we conclude that although young children receiving
IV aminoglycosides should have regular monitoring of renal
function and preferably receive the first dose of TSI under
supervision to monitor for immediate adverse effects. The data
does not support the requirement for audiometric monitoring on
a routine basis for either IV or inhaled exposure and no data to
support routine monitoring of renal function with TSI as these
drugs have an acceptable safety profile in preschool children
with CF.
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